CALC · CalciMedica, Inc.

No longer meets the screen criteria as of 2026-07-15 — TTM revenue = $0. The page is kept because the daily page for the day the insider bought links here, and that purchase still happened.

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.

Cap structure and valuation

Cap structure
SP	$0.78
SO	15.8M
Options	4.8M
Warrants	3.7M
FD SO	24.3M
MC	$19.0M

Cash	$8.2M
Total debt	—
EV	$10.8M

TTM Multiples
EV / Revenue	—
EV / EBITDA	—
MC / Net Income	—
EV / FCF	—
MC / FCF	—

Ownership & coverage
Institutional	35.5%
Insiders	27.5%
# Institutions	32
Analysts	2
Consensus	Buy
Avg target	$10.50

Short % float	33.9%
Days to cover	0.49

MC = SP × FD SO. EV = MC + Debt − Cash. SP = previous yfinance close. Balance-sheet figures as of 2026-05-07. Multiples use TTM (sum of last 4 quarters); shown as "—" when the denominator is zero or negative, or when fewer than four quarters are reported — a partial sum is not a trailing twelve months. Ownership & coverage per Yahoo Finance as of 2026-07-13 — institutional % is 13F-based, so it can lag a quarter and exceed 100% on share-count timing. Short interest per FINRA bi-monthly reporting, as of 2026-06-29; the float denominator can be unreliable on tiny floats.

Financial statements

	3/31/26	12/31/25	9/30/25	6/30/25
SG&A	2.13	1.28	1.77	2.57
R&D	3.48	3.11	3.85	4.05

Operating Income	(5.61)	(4.38)	(5.62)	(6.62)
Operating Income YoY %	13.6%	29.0%	2.1%	(1.4%)
EBITDA	(5.60)	(4.38)	(5.61)	(6.61)

Interest Expense	0.32	0.33	0.33	0.32
Other Income / (Expense)	10.91	(6.05)	(1.86)	0.99
Pretax Income	4.98	(10.76)	(7.80)	(5.96)
Tax Provision	0.00	0.00	0.00	0.00
Net Income	4.98	(10.76)	(7.80)	(5.96)
Net Income to Common	4.98	(10.76)	(7.80)	(5.96)

Diluted EPS	$0.30	-$0.69	-$0.52	-$0.40
Basic EPS	$0.31	-$0.69	-$0.52	-$0.40
Diluted Avg Shares	16.3	—	15.1	15.0
Basic Avg Shares	15.8	—	15.1	15.0

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
SG&A	7.74	7.89	9.73	22.22	5.84
R&D	14.49	15.23	14.48	15.86	8.35

Operating Income	(22.23)	(23.12)	(24.20)	(38.08)	(14.19)
Operating Income YoY %	3.8%	4.5%	36.4%	(168.3%)	—
EBITDA	(22.20)	(23.07)	(24.15)	(38.02)	(14.14)

Interest Expense	1.29	1.42	0.00	—	—
Other Income / (Expense)	3.98	(5.02)	10.50	3.72	6.37
Pretax Income	(19.54)	(29.56)	(13.70)	(34.36)	(7.82)
Tax Provision	0.00	0.00	0.00	0.00	0.00
Net Income	(19.54)	(29.56)	(13.70)	(34.36)	(7.82)
Net Income to Common	(19.54)	(29.56)	(13.70)	(34.36)	(7.82)

Diluted EPS	-$1.31	-$1.97	-$1.22	-$7.66	-$111.16
Basic EPS	-$1.30	-$1.97	-$1.22	-$7.66	-$111.16
Diluted Avg Shares	16.3	15.0	11.2	4.5	0.1
Basic Avg Shares	15.8	15.0	11.2	4.5	0.1

	3/31/26	12/31/25	9/30/25	6/30/25
Cash & Equivalents	8.16	11.52	5.47	5.92
Short-term Investments	0.00	1.50	8.61	12.04
Other Current Assets	—	0.51	0.77	1.01
Total Current Assets	8.55	13.53	14.85	18.96

Net PPE	0.04	0.05	0.05	0.10
Total Assets	8.61	13.59	14.91	19.08

Accounts Payable	1.68	1.16	1.13	1.91
Other Current Liabilities	3.64	2.62	2.55	1.56
Total Current Liabilities	5.31	3.78	3.68	3.48
Other Liabilities	4.40	16.45	11.50	9.50
Total Liabilities	9.71	20.23	15.18	12.98

Retained Earnings	(184.35)	(189.33)	(178.57)	(170.76)
Total Equity	(1.10)	(6.64)	(0.27)	6.10

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Cash & Equivalents	8.16	11.52	7.93	5.53	1.33
Short-term Investments	0.00	1.50	10.73	5.71	0.00
Other Current Assets	—	0.51	1.00	—	—
Total Current Assets	8.55	13.53	19.66	11.61	1.73

Net PPE	0.04	0.05	0.12	0.17	0.15
Operating Lease ROU	—	—	—	0.00	0.05
Other Assets	—	—	—	—	1.42
Total Assets	8.61	13.59	19.79	12.19	3.35

Accounts Payable	1.68	1.16	2.00	1.42	2.87
Current Lease Liabilities	—	—	—	—	0.20
Other Current Liabilities	3.64	2.62	1.69	2.61	1.71
Total Current Liabilities	5.31	3.78	3.68	4.03	4.78
Other Liabilities	4.40	16.45	1.70	—	7.80
Total Liabilities	9.71	20.23	5.38	4.03	12.58

Retained Earnings	(184.35)	(189.33)	(159.76)	(146.06)	(111.71)
Total Equity	(1.10)	(6.64)	14.41	8.16	(9.23)

	3/31/26	12/31/25	9/30/25	6/30/25
Net Income	4.98	(10.76)	(7.80)	(5.96)
D&A	0.01	0.01	0.01	0.01
Stock-Based Comp	0.56	0.62	0.62	1.18
Δ Working Cap & Other	(10.40)	5.28	2.39	(1.90)
Operating Cash Flow	(4.86)	(4.85)	(4.78)	(6.67)

CapEx	0.00	(0.01)	(0.01)	(0.01)
Other Investing	1.50	7.15	3.52	—
Investing Cash Flow	1.50	7.15	3.51	0.13

Stock Issuance	0.00	0.00	0.00	0.00
Other Financing	—	3.75	0.82	—
Financing Cash Flow	0.00	3.75	0.82	(0.10)

Free Cash Flow	(4.86)	(4.86)	(4.79)	(6.67)

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Net Income	(19.54)	(29.56)	(13.70)	(34.36)	(7.82)
D&A	0.04	0.05	0.06	0.06	0.05
Stock-Based Comp	2.98	2.97	2.31	12.04	1.81
Δ Working Cap & Other	(4.63)	5.37	(9.82)	(3.47)	(5.79)
Operating Cash Flow	(21.16)	(21.18)	(21.15)	(25.73)	(11.76)

CapEx	(0.02)	(0.03)	(0.01)	(0.08)	(0.00)
Other Investing	12.31	9.58	(4.42)	8.96	—
Investing Cash Flow	12.29	9.55	(4.42)	8.88	(0.00)

Stock Issuance	0.00	0.01	27.91	10.34	—
Other Financing	4.47	15.20	—	10.56	8.48
Financing Cash Flow	4.47	15.21	27.97	20.90	8.48

Free Cash Flow	(21.18)	(21.21)	(21.15)	(25.81)	(11.76)

	3/31/26	12/31/25	9/30/25	6/30/25
Current Ratio	1.61	3.58	4.04	5.45
Quick Ratio	—	—	—	—
Debt / Equity	-8.80	-3.05	-56.65	2.13
EBITDA Margin %	—	—	—	—
Working Capital	3.24	9.75	11.17	15.49
Net Debt	—	—	—	—
ROE %	(450.7%)	162.0%	2911.9%	(97.6%)
ROA %	57.8%	(79.2%)	(52.3%)	(31.2%)

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Current Ratio	1.61	3.58	5.34	2.88	0.36
Quick Ratio	—	—	—	—	—
Debt / Equity	-8.80	-3.05	0.37	0.49	-1.36
EBITDA Margin %	—	—	—	—	—
Working Capital	3.24	9.75	15.98	7.58	(3.05)
Net Debt	—	—	—	—	—
ROE %	1770.3%	445.1%	(95.1%)	(421.2%)	84.7%
ROA %	(227.0%)	(217.5%)	(69.2%)	(282.0%)	(233.6%)

Insider activity (last 2 years)

Date Filed	Reporter	Relationship	Trans. Date	Code	Shares	Price	Total Value
2026-06-29	Middleton Fred A	Director, 10% Owner	2026-06-25	P	248,972	$0.80	$199,999
2026-06-29	Hebbar Sudarshan	Officer (Chief Medical Officer)	2026-06-25	A	124,486	$0.80	$100,000
2026-06-29	WILSON ROBERT N	Director	2026-06-25	A	1,182,621	$0.80	$949,999
2026-06-29	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2026-06-25	A	186,729	$0.80	$149,999
2026-06-29	Leheny A. Rachel	Director, Officer (CHIEF EXECUTIVE OFFICER), 10% Owner	2026-06-25	A	186,729	$0.80	$149,999
2026-04-07	Bardin Stephen	Officer (Chief Financial Officer)	2025-04-05	A	67,728	—	$0
2026-04-07	Hebbar Sudarshan	Officer (Chief Medical Officer)	2025-04-05	A	91,173	—	$0
2026-04-07	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-04-05	A	83,358	—	$0
2026-04-07	Dunn Michael J.	Officer (President and COO)	2025-04-05	A	65,124	—	$0
2026-04-07	Stauderman Kenneth A.	Officer (Chief Scientific Officer)	2025-04-05	A	65,124	—	$0
2026-04-07	Leheny A. Rachel	Director, Officer (CHIEF EXECUTIVE OFFICER), 10% Owner	2025-04-05	A	148,482	—	$0
2025-10-14	Glicklich Alan	Director	2025-10-13	A	937	—	$0
2025-09-22	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-09-18	P	2,500	$3.07	$7,675
2025-09-17	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-09-15	P	3,400	$2.68	$9,105
2025-09-15	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-09-12	P	5,000	$3.12	$15,600
2025-09-11	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-09-09	P	2,343	$3.15	$7,378
2025-09-02	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-08-29	P	800	$2.74	$2,192
2025-09-02	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-08-28	P	9,200	$2.86	$26,340
2025-08-25	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-08-21	P	3,508	$2.79	$9,797
2025-08-21	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-08-20	P	2,000	$2.72	$5,440
2025-08-21	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-08-20	M	15,000	$1.53	$22,950
2025-08-21	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-08-20	M	(15,000)	$1.53	-$22,950
2025-08-21	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-08-19	P	1,000	$2.79	$2,790
2025-08-21	Hebbar Sudarshan	Officer (Chief Medical Officer)	2025-08-19	P	9,563	$2.82	$26,962
2025-08-19	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-08-15	P	5,076	$2.90	$14,709
2025-08-18	Hebbar Sudarshan	Officer (Chief Medical Officer)	2025-08-15	P	4,392	$2.79	$12,267
2025-08-18	Hebbar Sudarshan	Officer (Chief Medical Officer)	2025-08-14	P	1,584	$2.58	$4,095
2025-07-29	Stauderman Kenneth A.	Officer (Chief Scientific Officer)	2025-07-28	P	1,000	$3.96	$3,960
2025-07-29	Stauderman Kenneth A.	Officer (Chief Scientific Officer)	2025-07-25	S	(1,000)	$3.65	-$3,650
2025-07-23	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-07-22	P	1,500	$3.77	$5,662
2025-07-22	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-07-21	P	1,500	$3.37	$5,055
2025-07-21	Leheny A. Rachel	Director, Officer (CHIEF EXECUTIVE OFFICER), 10% Owner	2025-07-21	P	1,000	$3.40	$3,400
2025-07-18	WILSON ROBERT N	Director	2025-07-18	P	4,500	$2.87	$12,915
2025-07-18	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-07-18	P	2,000	$2.88	$5,760
2025-07-16	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-07-14	P	6,500	$2.43	$15,810
2025-07-15	Leheny A. Rachel	Director, Officer (CHIEF EXECUTIVE OFFICER), 10% Owner	2025-07-14	P	2,500	$2.47	$6,175
2025-07-10	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-07-09	P	5,000	$1.60	$8,024
2025-07-02	Stauderman Kenneth A.	Officer (Chief Scientific Officer)	2025-07-01	P	1,000	$1.85	$1,850
2025-06-27	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-06-26	P	4,500	$1.44	$6,483
2025-06-26	Bardin Stephen	Officer (Chief Financial Officer)	2025-06-26	P	2,000	$1.50	$3,005
2025-06-26	Hebbar Sudarshan	Officer (Chief Medical Officer)	2025-06-24	A	83,300	—	$0
2025-06-26	Bardin Stephen	Officer (Chief Financial Officer)	2025-06-24	A	20,000	—	$0
2025-06-26	Stauderman Kenneth A.	Officer (Chief Scientific Officer)	2025-06-24	A	47,125	—	$0
2025-06-26	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-06-24	A	72,750	—	$0
2025-06-26	Dunn Michael J.	Officer (President and COO)	2025-06-24	A	47,125	—	$0
2025-06-26	Leheny A. Rachel	Director, Officer (CHIEF EXECUTIVE OFFICER), 10% Owner	2025-06-24	A	77,625	—	$0
2025-06-26	Guerard Frederic	Director	2025-06-24	A	10,000	—	$0
2025-06-26	Guerard Frederic	Director	2025-06-24	A	5,000	—	$0
2025-06-26	Guerard Frederic	Director	2025-06-24	A	15,000	—	$0
2025-06-26	Guerard Frederic	Director	2025-06-24	A	10,000	—	$0
2025-06-26	Glicklich Alan	Director	2025-06-24	A	10,000	—	$0
2025-06-26	Glicklich Alan	Director	2025-06-24	A	4,166	—	$0
2025-06-26	Glicklich Alan	Director	2025-06-24	A	15,000	—	$0
2025-06-26	Glicklich Alan	Director	2025-06-24	A	10,000	—	$0
2025-06-26	Shaw Allan	Director	2025-06-24	A	10,000	—	$0
2025-06-26	Shaw Allan	Director	2025-06-24	A	8,594	—	$0
2025-06-26	Shaw Allan	Director	2025-06-24	A	26,250	—	$0
2025-06-26	Shaw Allan	Director	2025-06-24	A	10,000	—	$0
2025-06-26	WILSON ROBERT N	Director	2025-06-24	A	10,000	—	$0
2025-06-26	WILSON ROBERT N	Director	2025-06-24	A	12,031	—	$0
2025-06-26	WILSON ROBERT N	Director	2025-06-24	A	36,562	—	$0
2025-06-26	WILSON ROBERT N	Director	2025-06-24	A	10,000	—	$0
2025-06-26	MIDDLETON FRED A	Director, 10% Owner	2025-06-24	A	10,000	—	$0
2025-06-26	MIDDLETON FRED A	Director, 10% Owner	2025-06-24	A	6,562	—	$0
2025-06-26	MIDDLETON FRED A	Director, 10% Owner	2025-06-24	A	19,687	—	$0
2025-06-26	MIDDLETON FRED A	Director, 10% Owner	2025-06-24	A	10,000	—	$0
2025-06-13	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-06-11	P	5,000	$1.85	$9,250
2025-06-09	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-06-06	P	5,000	$1.77	$8,875
2025-06-09	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-06-05	P	5,100	$1.70	$8,670
2025-06-03	Bardin Stephen	Officer (Chief Financial Officer)	2025-05-30	P	1,000	$1.69	$1,690
2025-04-25	Bardin Stephen	Officer (Chief Financial Officer)	2025-04-23	A	130,000	—	$0
2025-04-25	Stauderman Kenneth A.	Officer (Chief Scientific Officer)	2025-04-23	A	125,000	—	$0
2025-04-25	Dunn Michael J.	Officer (President and COO)	2025-04-23	A	125,000	—	$0
2025-04-25	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2025-04-23	A	160,000	—	$0
2025-04-25	Hebbar Sudarshan	Officer (Chief Medical Officer)	2025-04-23	A	175,000	—	$0
2025-04-25	Leheny A. Rachel	Director, Officer (CHIEF EXECUTIVE OFFICER), 10% Owner	2025-04-23	A	285,000	—	$0
2025-01-16	Glicklich Alan	Director	2025-01-15	A	20,000	—	$0
2024-12-06	MIDDLETON FRED A	Director, 10% Owner	2024-12-06	P	4,800	$2.65	$12,720
2024-11-06	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2023-05-17	P	3,000	$2.68	$8,040
2024-11-05	Sanderling Venture Partners VI Co Investment Fund LP	10% Owner	2024-11-01	P	86,867	$3.75	$325,751
2024-11-05	Sanderling Venture Partners VI Co Investment Fund LP	10% Owner	2024-11-01	P	877	$3.75	$3,289
2024-11-05	MIDDLETON FRED A	Director, 10% Owner	2024-11-01	P	20,000	$3.75	$75,000
2024-11-05	MIDDLETON FRED A	Director, 10% Owner	2024-11-01	P	86,867	$3.75	$325,751
2024-11-05	MIDDLETON FRED A	Director, 10% Owner	2024-11-01	P	877	$3.75	$3,289
2024-11-01	Leheny A. Rachel	Director, Officer (CHIEF EXECUTIVE OFFICER), 10% Owner	2024-11-01	P	20,000	$3.75	$75,000
2024-11-01	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2024-11-01	P	53,333	$3.75	$199,999
2024-11-01	WILSON ROBERT N	Director	2024-11-01	P	53,333	$3.75	$199,999
2024-09-11	Dunn Michael J.	Officer (President and COO)	2024-09-09	M	11,761	$1.39	$16,348
2024-09-11	Dunn Michael J.	Officer (President and COO)	2024-09-09	M	(11,761)	—	$-0
2024-08-28	Guerard Frederic	Director	2024-08-27	A	10,000	—	$0
2024-08-28	BJERKHOLT ERIC	Director	2024-08-27	A	10,000	—	$0
2024-08-28	Shaw Allan	Director	2024-08-27	A	10,000	—	$0
2024-08-28	MIDDLETON FRED A	Director, 10% Owner	2024-08-27	A	10,000	—	$0
2024-08-28	WILSON ROBERT N	Director	2024-08-27	A	10,000	—	$0
2024-08-28	Dunn Michael J.	Officer (President and COO)	2024-08-27	A	62,500	—	$0
2024-08-28	Stauderman Kenneth A.	Officer (Chief Scientific Officer)	2024-08-27	A	62,500	—	$0
2024-08-28	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2024-08-27	A	77,500	—	$0
2024-08-28	Hebbar Sudarshan	Officer (Chief Medical Officer)	2024-08-27	A	82,500	—	$0
2024-08-28	Leheny A. Rachel	Director, Officer (CHIEF EXECUTIVE OFFICER), 10% Owner	2024-08-27	A	115,000	—	$0
2024-08-27	Leheny A. Rachel	Director, Officer (CHIEF EXECUTIVE OFFICER), 10% Owner	2024-08-27	P	1,000	$4.19	$4,190
2024-08-26	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2024-08-23	P	2,000	$3.58	$7,157
2024-08-26	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2024-08-23	P	3,000	$3.57	$10,710
2024-08-26	WILSON ROBERT N	Director	2024-08-23	P	54,000	$3.72	$200,826
2024-08-22	Roberts Eric W	Director, Officer (CHIEF BUSINESS OFFICER), 10% Owner	2024-08-21	P	5,000	$4.04	$20,200
2024-07-02	WILSON ROBERT N	Director	2024-06-28	P	51,278	$3.52	$180,499
2024-07-01	WILSON ROBERT N	Director	2024-06-27	P	8,443	$3.23	$27,305